Valvosoft First-In-Human Study in Severe Symptomatic Aortic Stenosis

Inclusion Criteria: * Subjects suffering from severe symptomatic aortic valve stenosis according to ESC 2017 definition, including subjects with a bicuspid valve. * Patient is not eligible for TAVR/SAVR according to local Heart Team. * Age ≥18 years. * Subjects who are willing to provide a written informed consent prior to participating in the study. * Subjects who can comply with the study follow up or other study requirements. * Patient is eligible for the Valvosoft procedure according to CRC. Exclusion Criteria: * Subjects with any electrical device implanted. * Subjects with unstable arrhythmia not controlled by medical treatment. * Subjects with implanted mechanical valve in any position or bio prosthetic valve in aortic position. * Subjects with complex congenital heart disease. * Chest deformity. * Cardiogenic shock. * History of heart transplant. * Subjects requiring other cardiac surgery procedures (bypass graft surgery, mitral valve procedure, tricuspid valve procedure) within one month after treatment. * Thrombus in heart. * Acute myocardial infarction (MI), stroke or transient ischemic attack (TIA) within one month prior to enrolment\*. * Subjects who are pregnant or nursing. * Subjects who are participating in another research study for which the primary endpoint has not been reached.